Sadelain M - Search Results

1

Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.

Dobrin A, Lindenbergh PL, Shi Y, Perica K, Xie H, Jain N, Chow A, Wolchok JD, Merghoub T, Sadelain M, Hamieh M. Dobrin A, et al. Among authors: sadelain m. Nat Cancer. 2024 May;5(5):760-773. doi: 10.1038/s43018-024-00744-x. Epub 2024 Mar 19. Nat Cancer. 2024. PMID: 38503896

2

Targeting tumours with genetically enhanced T lymphocytes.

Sadelain M, Rivière I, Brentjens R. Sadelain M, et al. Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971. Nat Rev Cancer. 2003. PMID: 12509765 Review.

3

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M. Brentjens RJ, et al. Among authors: sadelain m. Nat Med. 2003 Mar;9(3):279-86. doi: 10.1038/nm827. Epub 2003 Feb 10. Nat Med. 2003. PMID: 12579196

4

Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.

Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, Wulderk M, Jeffers Y, Sadelain M, Hohenhaus AE, Segal N, Gregor P, Engelhorn M, Riviere I, Houghton AN, Wolchok JD. Bergman PJ, et al. Among authors: sadelain m. Clin Cancer Res. 2003 Apr;9(4):1284-90. Clin Cancer Res. 2003. PMID: 12684396 Clinical Trial.

5

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.

Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. Gregor PD, et al. Among authors: sadelain m. Vaccine. 2004 Apr 16;22(13-14):1700-8. doi: 10.1016/j.vaccine.2003.10.048. Vaccine. 2004. PMID: 15068853

6

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.

Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston WD, Houghton AN, Scher HI. Gregor PD, et al. Among authors: sadelain m. Int J Cancer. 2005 Sep 1;116(3):415-21. doi: 10.1002/ijc.21014. Int J Cancer. 2005. PMID: 15800947 Free PMC article.

7

The pharmacology of second-generation chimeric antigen receptors.

van der Stegen SJ, Hamieh M, Sadelain M. van der Stegen SJ, et al. Among authors: sadelain m. Nat Rev Drug Discov. 2015 Jul;14(7):499-509. doi: 10.1038/nrd4597. Nat Rev Drug Discov. 2015. PMID: 26129802 Free PMC article. Review.

8

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Eyquem J, et al. Among authors: sadelain m. Nature. 2017 Mar 2;543(7643):113-117. doi: 10.1038/nature21405. Epub 2017 Feb 22. Nature. 2017. PMID: 28225754 Free PMC article.

9

Therapeutic T cell engineering.

Sadelain M, Rivière I, Riddell S. Sadelain M, et al. Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Nature. 2017. PMID: 28541315 Free PMC article. Review.

10

Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, Hendrickson RC, Brennan CW, Sadelain M. Perna F, et al. Among authors: sadelain m. Cancer Cell. 2017 Oct 9;32(4):506-519.e5. doi: 10.1016/j.ccell.2017.09.004. Cancer Cell. 2017. PMID: 29017060 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

312 results

Search Page

Filters